Clinical Trials

17 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT03388190 2026-02-13

METIMMOX

80 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

27 enrolled 9 charts

Uveal Melanoma

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Prostatic Neoplasms

NCT04401774 2026-01-27

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

14 enrolled

CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

NCT05136677 2026-01-23

CheckMate 6DW

Other solid neoplasmThoracic

102 enrolled

Mesothelioma, Malignant

NCT03829722 2026-01-22

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

26 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT03285321 2026-01-20

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

105 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

20 enrolled 13 charts

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT04717154 2026-01-06

INSPIRE

69 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT03405155 2025-12-31

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

26 enrolled

Melanoma

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Prostatic Neoplasms

NCT03172624 2025-12-18

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

64 enrolled 9 charts

Salivary Gland Neoplasms

NCT02939300 2025-11-14

Ipilimumab and Nivolumab in Leptomeningeal Metastases

18 enrolled 17 charts

Meningeal Carcinomatosis

NCT03021993 2025-11-12

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

17 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT02823990 2025-11-10

TG4010 and Nivolumab in Patients With Lung Cancer

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02060188 2025-11-06

CheckMate142

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03557359 2025-11-03

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

35 enrolled 9 charts

Glioma, Recurrence

NCT04019964 2025-10-23

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

8 enrolled

Prostatic Neoplasms

NCT03573947 2025-10-14

TOP1705

46 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03075423 2025-09-26

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

316 enrolled

Carcinoma, Renal Cell

NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

100 enrolled 13 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04988841 2025-08-28

PICASSO

70 enrolled

Melanoma

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

2 enrolled 10 charts

Neoplasms, Pancreatic Neoplasms

NCT03890952 2025-07-24

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

40 enrolled

Brain Neoplasms

NCT02553642 2025-07-22

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

DermatologicGenitourinary

81 enrolled 12 charts

Urinary Bladder Neoplasms, Melanoma

NCT03382561 2025-07-03

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

160 enrolled 12 charts

Small Cell Lung Carcinoma

NCT03442569 2025-07-01

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

56 enrolled 13 charts

Colonic Neoplasms

NCT03173950 2025-06-29

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

133 enrolled

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningioma, Pinealoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms

NCT03246958 2025-06-19

Nivolumab Plus Ipilimumab in Thyroid Cancer

53 enrolled 19 charts

Thyroid Neoplasms

NCT03642067 2025-06-15

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

59 enrolled 11 charts

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

MyeloidOther hematologic neoplasm

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03297593 2025-06-06

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

74 enrolled

Carcinoma, Renal Cell

NCT03639935 2025-06-03

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

32 enrolled 14 charts

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03250273 2025-05-28

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

44 enrolled 19 charts

Neoplasm Metastasis, Pancreatic Neoplasms, Cholangiocarcinoma

NCT03618641 2025-05-14

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

34 enrolled 15 charts

Melanoma

NCT03944915 2025-05-11

DEPEND

35 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03570619 2025-05-08

IMPACT

56 enrolled 18 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03107182 2025-05-06

OPTIMA-II

72 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

NCT03342911 2025-04-24

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

34 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

14 enrolled 8 charts

Uveal Melanoma

NCT04704154 2025-04-18

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

CNSGastrointestinalHead & Neck

175 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Glioblastoma

NCT04907539 2025-04-16

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

25 enrolled 22 charts

Colorectal Neoplasms

NCT02196961 2025-04-09

ADMEC-O

180 enrolled

Carcinoma, Merkel Cell

NCT02523313 2025-04-09

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

167 enrolled

Melanoma

NCT03591731 2025-04-01

NIPINEC

185 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT02631746 2025-03-14

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

LymphoidOther hematologic neoplasm

3 enrolled 8 charts

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04072198 2025-03-13

NIVACOR

73 enrolled

Colorectal Neoplasms

NCT05061017 2025-03-07

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)